PubRank

Gert De Meerleer

Author PubWeight™ 38.66‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 2009 2.25
2 Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008 2.00
3 Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys 2010 1.33
4 Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008 1.20
5 Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 2007 1.20
6 Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity. Radiother Oncol 2006 1.16
7 Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 2014 1.14
8 Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer 2014 1.13
9 Analysis of prostate bed motion using daily cone-beam computed tomography during postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 2010 1.13
10 Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2012 1.11
11 Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2014 1.05
12 A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010 1.02
13 Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer. Radiother Oncol 2009 1.01
14 High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 2011 1.01
15 Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation. Strahlenther Onkol 2009 0.96
16 Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome. Radiother Oncol 2013 0.95
17 Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys 2012 0.94
18 Delineation of the postprostatectomy prostate bed using computed tomography: interobserver variability following the EORTC delineation guidelines. Int J Radiat Oncol Biol Phys 2011 0.93
19 Radiotherapy and surgery-an indispensable duo in the treatment of retroperitoneal sarcoma. Cancer 2011 0.93
20 Acute radiation-induced nocturia in prostate cancer patients is associated with pretreatment symptoms, radical prostatectomy, and genetic markers in the TGFβ1 gene. Int J Radiat Oncol Biol Phys 2012 0.88
21 Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity. Int J Radiat Oncol Biol Phys 2012 0.86
22 Evaluation of the Sinmed Mastercouch as replacement for a standard couch. Radiother Oncol 2005 0.84
23 Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases. Neurol Sci 2012 0.84
24 Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys 2008 0.83
25 High-dose adjuvant radiotherapy after radical prostatectomy with or without androgen deprivation therapy. Int J Radiat Oncol Biol Phys 2011 0.82
26 Salvage radiotherapy: a plea for dose-escalation with intensity-modulated radiotherapy. Eur J Cancer 2012 0.82
27 The role of nuclear medicine in the prediction and detection of radiation-associated normal pulmonary and cardiac damage. J Nucl Med 2003 0.82
28 Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer. Int J Radiat Oncol Biol Phys 2009 0.80
29 Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 2007 0.80
30 Prostate cancer pain management: EAU guidelines on pain management. World J Urol 2012 0.80
31 Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study. Int J Gynecol Cancer 2012 0.79
32 Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer. Adv Urol 2011 0.79
33 Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy. Radiother Oncol 2013 0.79
34 Volumetric modulated arc therapy for delivery of prostate radiotherapy: in regard to Palma et al. (Int J Radiat Oncol Biol Phys 2008;70:996-1001). Int J Radiat Oncol Biol Phys 2009 0.78
35 Point/counterpoint. High intensity focused ultrasound may be superior to radiation therapy for the treatment of early stage prostate cancer. Med Phys 2011 0.78
36 Completion surgery after intensity-modulated arc therapy in the treatment of locally advanced cervical cancer: feasibility, surgical outcome, and oncologic results. Int J Gynecol Cancer 2013 0.76
37 Developments in external beam radiotherapy for prostate cancer. Urology 2013 0.76
38 Improving positioning in high-dose radiotherapy for prostate cancer: safety and visibility of frequently used gold fiducial markers. Int J Radiat Oncol Biol Phys 2011 0.75
39 Re: Michael L. Eisenberg, Benjamin J. Davies, Matthew R. Cooperberg, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010;57:622-30. Eur Urol 2010 0.75
40 Image-guided radiation therapy: many roads lead to Rome? Int J Radiat Oncol Biol Phys 2008 0.75
41 Intensity-modulated radiotherapy: the gold standard for postprostatectomy irradiation? Eur Urol 2011 0.75
42 Early biomarkers related to secondary primary cancer risk in radiotherapy treated prostate cancer patients: IMRT versus IMAT. Radiother Oncol 2013 0.75
43 Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience. Acta Oncol 2014 0.75
44 Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate Cancer. Urol Int 2017 0.75